MCE - Delayed Quote EUR

Laboratorios Farmaceuticos Rovi, S.A. (ROVI.MC)

79.40 -0.05 (-0.06%)
At close: April 19 at 5:35 PM GMT+2

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
NameTitlePayExercisedYear Born
Mr. Ivan Lopez-Belmonte Encina Second Deputy Chairman & GM of Commercial and Development 472k -- --
Mr. Javier Lopez-Belmonte Encina First Deputy Chairman, GM of Industrial Operations & CFO 474k -- --
Mr. Juan Lopez-Belmonte Encina Chairman & CEO 1.15M -- --
Marta Campos Martínez Head of Investor Relations -- -- --
Ms. Mercedes Benítez del Castillo Sánchez Legal Department Manager -- -- --
Ms. Beatriz Ávila Alcalde Sales Manager -- -- --
Ms. Rosario Perucha Pérez Marketing Manager -- -- --
Mr. Francisco Javier Angulo García Human Resources Manager -- -- --
Mr. Gabriel Nunez Fernandez Secretary -- -- --

Laboratorios Farmaceuticos Rovi, S.A.

Calle José Isbert, 2
Pozuelo de Alarcón
Madrid, 28223
Spain
34 91 021 30 00 https://www.rovi.es
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
1,925

Description

Laboratorios Farmaceuticos Rovi, S.A. engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally. The company provides products for cardiology, osteoarticular/women's health, anesthesia /pain, diagnostic imaging contrast agents, central nervous system, urology, endocrinology, respiratory, and primary healthcare areas. Its principal products include Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa; and hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+, Empowermr, and CT Express, Fibrilin, and Sodium Heparin Rovi. It also provides contract-manufacturing services to other companies for a range of pharmaceutical forms, including prefilled syringes, vials, suppositories, tablets, and sachets. Laboratorios Farmaceuticos Rovi, S.A. was incorporated in 1946 and is headquartered in Madrid, Spain. Laboratorios Farmaceúticos Rovi, S.A. is a subsidiary of Norbel Inversiones, S.L.

Corporate Governance

Laboratorios Farmaceuticos Rovi, S.A.’s ISS Governance QualityScore as of April 1, 2024 is 4. The pillar scores are Audit: 7; Board: 7; Shareholder Rights: 6; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Jul 03, 2023
    Ex-Dividend Date

Upcoming Events

May 08, 2024
Laboratorios Farmaceuticos Rovi, S.A. Earnings Call

Related Tickers